<https://rdf.molmedb.upol.cz/reference/ref3190> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM490050>,
		<https://rdf.molmedb.upol.cz/interaction/membrane46>;
	<http://purl.org/ontology/bibo/doi> "10.1016/j.bmcl.2013.04.006"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM489486>;
	<http://purl.org/ontology/bibo/pmid> "23628336"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method71>,
		<https://identifiers.org/molmedb/MM489487>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/bibliographicCitation> "Scott JS, Brocklehurst KJ, Brown HS, Clarke DS, Coe H, Groombridge SD, Laber D, MacFaul PA, McKerrecher D, Schofield P.: Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human. Bioorg Med Chem Lett, Volume 23 (11), 2013"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1009541> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3190> .
<https://rdf.molmedb.upol.cz/interaction/int1009540> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3190> .
<https://rdf.molmedb.upol.cz/interaction/int1008785> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3190> .
<https://rdf.molmedb.upol.cz/interaction/int1008784> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3190> .
<https://rdf.molmedb.upol.cz/interaction/int1008783> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3190> .